Floatz logo

Nabilone

FTD

Simon Ducharme, MDSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the FTD cohort.

Asset / SponsorPhaseRating
PITTSBURGH COMPOUND B UNLABELLED
Mayo Clinic
Phase 4BB
FLORTAUCIPIR
Mayo Clinic
Phase 2B
Wve-004
Wave Life Sciences USA, Inc.
Phase 1/2CCC
ER-176
Mayo Clinic
D

Same molecule, other indications

Nabilone is also rated in:

neuralgiaDormant
BBB
Indicative ·
72 / 100
View asset →
Antineoplastic Combined Chemotherapy ProtocolsDormant
BB
Indicative ·
69 / 100
View asset →
peripheral neuropathyDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →